Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. - Wikidata - wikimedia - TriplyDB

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

http://www.wikidata.org/entity/Q34743802

about

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression Phase II study of everolimus in metastatic urothelial cancer.Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer Novel molecular targets for the therapy of urothelial carcinoma.Animal models of urinary bladder cancer and their application to novel drug discovery.Optimal treatment for metastatic bladder cancer.Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.mTOR inhibitors in urinary bladder cancer.Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063).Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis.Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma

P2860

Q28743074-04B4A614-0E8E-4403-853C-89754DEAC711 Q33606604-7F1E03CE-9951-4829-9705-004C1F19B90C Q33793812-01C83377-9BB1-4AFD-A3CA-592F352F2714 Q34000632-B6F7A128-7B8E-4D8B-9BDF-02A492CB7B9B Q34305503-B99B2394-6987-423C-9F6F-B3D1F7792FD9 Q34993621-2A7782B6-9DB2-48A1-81BE-C475B10EC2B0 Q35505109-C3D31A5A-67E4-4164-8029-F7E2B5E03DFB Q35638497-D9B416E2-575B-4443-A0B9-93461E2807A1 Q36061127-9E85B7EC-163D-4CAE-A490-6DE6C4BB3C6F Q36384361-FD8CFF07-19C6-4033-9ADA-6EC706D53E01 Q37446067-409C13D5-EE30-4432-91AA-15FB444942D9 Q38003195-8F715547-17A8-4CE3-8710-8ED2842DD3BF Q38199547-68278513-2853-4084-B3A6-CDB3B97E04F9 Q38233326-A2CF7B06-3480-4DE1-93F0-B5DDBD5CEEAC Q38427265-2AB3C2AA-DB26-4416-9374-976152C85D88 Q38735342-67BE9532-2FA1-4847-8336-BBC220CD1D76 Q38737064-CCE17D89-1DB0-4E30-B113-536B399F2711 Q39315907-FC8A5681-D1C0-4777-AAFC-32D5E5CD2FBE Q40197490-368F443C-2FDD-41A6-9CD4-31232A256B3D Q40447356-141A65BC-9876-4455-95CB-158603430F55 Q48007361-80B7E710-0EA5-4AF4-8582-1EDCFD62B67E Q55239950-854FD4C7-CA49-4481-BE31-03AEB9F13069 Q58694370-CFA809DF-4D97-4E88-AF41-A05143E92089

P2860

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

http://www.wikidata.org/entity/Q34743802

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@ast

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@en

Effects of mTOR inhibitor everolimus

@nl

type

label

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@ast

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@en

Effects of mTOR inhibitor everolimus

@nl

prefLabel

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@ast

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@en

Effects of mTOR inhibitor everolimus

@nl

P1433

Q34743802-7232870C-CFB3-4071-908A-D3E4F8CE7CE2

P1476

Q34743802-0B6527EC-F5D4-4DFB-97F5-2BC3D43A7899

P2093

Q34743802-201E47BF-C9C9-4E40-8FB0-5BF3705E30CD

Q34743802-248246DD-C44E-4293-958F-036E754436B0

Q34743802-3798B825-58C7-4F0E-ADE4-BB5EC7D19989

Q34743802-3F9F1A53-CF0B-4910-AC97-E39D81A6DDBC

Q34743802-46E9CF3A-A0CA-48A9-9BBE-F97899C7E0B2

Q34743802-487070A0-8754-488F-A713-EE9D11C24E30

Q34743802-51E7A780-A784-4B2C-BD65-00BEF9924C37

Q34743802-77D62B1D-4D70-4398-B122-BBA4180FFE21

Q34743802-8D5E156A-01BB-49AF-BF93-C6EB1C3874C4

Q34743802-DBE9B1BE-4149-4A5D-B7F3-81DBB91C81E6

P2860

Q34743802-07B3F91C-0416-4E1A-BCDA-7286220CD3B0

Q34743802-08565591-5BFE-40F0-9532-0A49B6F72D70

Q34743802-0896498B-84A2-48CC-BD31-CFE318BC7C3D

Q34743802-0A0A384D-698F-4106-BF21-2B5E999DF23E

Q34743802-0AF28D89-33CC-4DC7-A9D6-CA9EFEA2178E

Q34743802-13C87EEE-B41C-492F-9E8C-7827641AAAFA

Q34743802-1F752DC0-C26F-4602-B2DA-9231E0F959C4

Q34743802-24F07A75-6D0A-41DA-B741-9C409C5979B0

Q34743802-368A2690-0F5E-437A-87C6-28BC8E744C68

Q34743802-38548EB8-8ACC-45EC-B466-77AFD8C06F4D

P304

Q34743802-FBF4981B-315B-42C5-A7BF-71B3C601833C

P31

Q34743802-F5662839-7607-45D7-A47C-427CAB1CF439

P356

Q34743802-DA6C9C76-88CD-48D0-86A5-4DE51355F9B6

P407

Q34743802-CF0BB098-5494-4FC7-A76C-C5AE62DA42B2

P433

Q34743802-B38B734C-9427-4782-8CF1-25A803DACC02

P478

Q34743802-3DFC67C8-CA8A-4786-9AE3-333A43447E85

P577

Q34743802-5BAE8101-1770-4EEA-805A-1597E5C71AB8

P5875

Q34743802-5A55B457-E9AF-4CC5-87E6-28BDDD2B5D4C

P698

Q34743802-62002BE7-15BC-4908-828D-FAE4326CA375

P932

Q34743802-D8FA32D2-A5DF-4D42-AB89-18F29652325D

P356

1078-0432.CCR-09-3202

P1433

Clinical Cancer Research

P1476

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

@en

P2093

Ali Dadbin

http://www.w3.org/2001/XMLSchema#string

Anita L Sabichi

http://www.w3.org/2001/XMLSchema#string

David J McConkey

http://www.w3.org/2001/XMLSchema#string

Diana Urbauer

http://www.w3.org/2001/XMLSchema#string

Edmund Chiong

http://www.w3.org/2001/XMLSchema#string

H Barton Grossman

http://www.w3.org/2001/XMLSchema#string

I-Ling Lee

http://www.w3.org/2001/XMLSchema#string

Loleta Harris

http://www.w3.org/2001/XMLSchema#string

Rian J Dickstein

http://www.w3.org/2001/XMLSchema#string

Tiewei Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the mTOR signaling network for cancer therapy

Current development of mTOR inhibitors as anticancer agents

Upstream and downstream of mTOR

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

Cancer statistics, 2007

Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway.

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.

Therapeutic targets: MTOR and related pathways.

Somatic mutation of PTEN in bladder carcinoma

mTOR, translation initiation and cancer.

P304

2863-2873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-3202

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50420002

http://www.w3.org/2001/XMLSchema#string

P698

21415218

http://www.w3.org/2001/XMLSchema#string

P932

4272218

http://www.w3.org/2001/XMLSchema#string